NCLT clears shareholder vote for Privi Speciality Chemicals merger
As filed · Privi Speciality Chemicals Limited has informed the Exchange about Notice of Meeting of Equity Shareholders (Meeting) of the Company in the matter of Scheme of Amalgamation scheduled to be held on on
What happened
FactThe NCLT Mumbai Bench, by order dated 7 September 2026, dispensed with creditor meetings for the proposed amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited into Privi Speciality Chemicals Limited. Privi Speciality Chemicals’ shareholder meeting will be held through OAVM on 27 October 2026 to consider the scheme.
Why it matters
CapitSignal interpretationA merger fixes a share-exchange ratio, which permanently sets how much of the combined company existing holders own.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Guidance
WithdrawnOn track to achieve the vision of Rs 5,000 Cr revenue and Rs 1,000 Cr + EBITDA by FY29-30, representing more than 2x growth.
Our JV with PRIGIV is progressing as per expectations and we expect meaningful contributions to keep coming ahead.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Swap ratio and its valuation basis
- Regulatory and NCLT approvals required
- Appointed date
- On track to achieve the vision of Rs 5,000 Cr revenue and Rs 1,000 Cr + EBITDA by FY29-30, representing more t (management committed by FY30)
- we are confident of achieving 20%, maintaining 20% CAGR with similar EBITDA margins. (management committed by FY27)
Evidence
- Privi Speciality Chemicals Limited has informed the Exchange about Notice of Meeting of Equity Shareholders (Meeting) of the Company in the matter of Scheme of Amalgamation scheduled to be held on on Tuesday, October 27, 2026, at 12.30 p.m.(opens the original filing in a new tab)
- Earlier statement · Q1 FY26
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- The scheme has advanced to the shareholder-approval stage, while creditor meetings for the transferor and transferee companies have been dispensed with. Completion remains subject to the shareholder meeting and the amalgamation process.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%